Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of spironolactone in hypokalemic CAPD patients
TCTR20130314001Phase 3Active, not recruiting
- Sponsor
- Burapha University
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in hypokalemia, end-stage kidney disease (ESKD), sponsored by Burapha University. Started Mar 2013; status: active, not recruiting.
02
Drugs
spironolactone
03
Conditions
hypokalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20130314001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20130314001.